Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry
Purpose: To assess short-term efficacy of a single injection of brolucizumab in neovascular AMD. Methods: This was a multicenter, retrospective chart review of 25 eyes of 25 patients who received a single injection of brolucizumab. Visual acuity (VA) and optical coherence tomography (OCT) features s...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2023;volume=71;issue=10;spage=3375;epage=3380;aulast=Joshi |
| _version_ | 1797649311491686400 |
|---|---|
| author | Shrinivas Joshi Lalit Verma Guruprasad Ayachit Rajashree Salvi Yusra Asad Avnindra Gupta Anuja Patil Apoorva Ayachit |
| author_facet | Shrinivas Joshi Lalit Verma Guruprasad Ayachit Rajashree Salvi Yusra Asad Avnindra Gupta Anuja Patil Apoorva Ayachit |
| author_sort | Shrinivas Joshi |
| collection | DOAJ |
| description | Purpose: To assess short-term efficacy of a single injection of brolucizumab in neovascular AMD. Methods: This was a multicenter, retrospective chart review of 25 eyes of 25 patients who received a single injection of brolucizumab. Visual acuity (VA) and optical coherence tomography (OCT) features such as central subfield thickness (CSFT), subretinal fluid (SRF), intraretinal fluid, and pigment epithelial detachment (PED) were recorded at baseline, first month, and third month. Results: Of the 25 eyes, 14 eyes were treatment-naïve and 11 eyes had received previous injections. VA improved from 0.68 ± 0.59 log MAR at baseline to 0.31 ± 0.43 log MAR at the end of 3 months. SRF height in first and third month was significantly reduced from baseline (P < 0.001). Subretinal hyperreflective material height significantly reduced from baseline (P value 0.008 at first month and 0.01 at third month, respectively). CSFT was 464.16 ± 247.97 microns at baseline and showed a significant reduction in first month (P < 0.001) and third month (P < 0.001). There was a significant reduction of PED height from baseline at both follow-ups. None of the eyes showed a recurrence of fluid at the end of 3 months. Conclusion: Our study demonstrated sustained improvement in VA and OCT parameters after a single injection of brolucizumab at 3 months. A longer follow-up may demonstrate even farther effects of a single injection. |
| first_indexed | 2024-03-11T15:45:20Z |
| format | Article |
| id | doaj.art-9a8682d240ff402d84c9c8907cb7f892 |
| institution | Directory Open Access Journal |
| issn | 0301-4738 1998-3689 |
| language | English |
| last_indexed | 2024-03-11T15:45:20Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj.art-9a8682d240ff402d84c9c8907cb7f8922023-10-26T06:49:35ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892023-01-0171103375338010.4103/IJO.IJO_210_23Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometryShrinivas JoshiLalit VermaGuruprasad AyachitRajashree SalviYusra AsadAvnindra GuptaAnuja PatilApoorva AyachitPurpose: To assess short-term efficacy of a single injection of brolucizumab in neovascular AMD. Methods: This was a multicenter, retrospective chart review of 25 eyes of 25 patients who received a single injection of brolucizumab. Visual acuity (VA) and optical coherence tomography (OCT) features such as central subfield thickness (CSFT), subretinal fluid (SRF), intraretinal fluid, and pigment epithelial detachment (PED) were recorded at baseline, first month, and third month. Results: Of the 25 eyes, 14 eyes were treatment-naïve and 11 eyes had received previous injections. VA improved from 0.68 ± 0.59 log MAR at baseline to 0.31 ± 0.43 log MAR at the end of 3 months. SRF height in first and third month was significantly reduced from baseline (P < 0.001). Subretinal hyperreflective material height significantly reduced from baseline (P value 0.008 at first month and 0.01 at third month, respectively). CSFT was 464.16 ± 247.97 microns at baseline and showed a significant reduction in first month (P < 0.001) and third month (P < 0.001). There was a significant reduction of PED height from baseline at both follow-ups. None of the eyes showed a recurrence of fluid at the end of 3 months. Conclusion: Our study demonstrated sustained improvement in VA and OCT parameters after a single injection of brolucizumab at 3 months. A longer follow-up may demonstrate even farther effects of a single injection.http://www.ijo.in/article.asp?issn=0301-4738;year=2023;volume=71;issue=10;spage=3375;epage=3380;aulast=Joshibrolucizumabneovascular age-related macular degenerationpigment epithelial detachmentsubretinal fluidsubretinal hyperreflective materialtype 1 macular neovascularization |
| spellingShingle | Shrinivas Joshi Lalit Verma Guruprasad Ayachit Rajashree Salvi Yusra Asad Avnindra Gupta Anuja Patil Apoorva Ayachit Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry Indian Journal of Ophthalmology brolucizumab neovascular age-related macular degeneration pigment epithelial detachment subretinal fluid subretinal hyperreflective material type 1 macular neovascularization |
| title | Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry |
| title_full | Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry |
| title_fullStr | Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry |
| title_full_unstemmed | Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry |
| title_short | Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry |
| title_sort | efficacy of a single injection of brolucizumab in neovascular age related macular degeneration on visual acuity and micromorphometry |
| topic | brolucizumab neovascular age-related macular degeneration pigment epithelial detachment subretinal fluid subretinal hyperreflective material type 1 macular neovascularization |
| url | http://www.ijo.in/article.asp?issn=0301-4738;year=2023;volume=71;issue=10;spage=3375;epage=3380;aulast=Joshi |
| work_keys_str_mv | AT shrinivasjoshi efficacyofasingleinjectionofbrolucizumabinneovascularagerelatedmaculardegenerationonvisualacuityandmicromorphometry AT lalitverma efficacyofasingleinjectionofbrolucizumabinneovascularagerelatedmaculardegenerationonvisualacuityandmicromorphometry AT guruprasadayachit efficacyofasingleinjectionofbrolucizumabinneovascularagerelatedmaculardegenerationonvisualacuityandmicromorphometry AT rajashreesalvi efficacyofasingleinjectionofbrolucizumabinneovascularagerelatedmaculardegenerationonvisualacuityandmicromorphometry AT yusraasad efficacyofasingleinjectionofbrolucizumabinneovascularagerelatedmaculardegenerationonvisualacuityandmicromorphometry AT avnindragupta efficacyofasingleinjectionofbrolucizumabinneovascularagerelatedmaculardegenerationonvisualacuityandmicromorphometry AT anujapatil efficacyofasingleinjectionofbrolucizumabinneovascularagerelatedmaculardegenerationonvisualacuityandmicromorphometry AT apoorvaayachit efficacyofasingleinjectionofbrolucizumabinneovascularagerelatedmaculardegenerationonvisualacuityandmicromorphometry |